Faster FDA Timelines Move Multiples. Make The MYNZ Timeline Visible

Recent priority reviews remind everyone that time to decision is a pricing lever. When the path and dates are clear, burn drops, partners lean in, and the market pays a higher multiple for the same asset.

For screening, the U.S. already reimburses approved noninvasive CRC tests every three years. The gate for MYNZ is execution, not a new code. Clinically, pooled next gen ColoAlert performance is about 92% CRC sensitivity, 82% advanced adenomas, and 95.8% high grade dysplasia. The need is huge. CRC is \~1.9M new cases and \~935k deaths a year. Five year survival is near 90% when localized and \~13% when distant.

What would tighten the timeline and likely the multiple: a dated feasibility read with endpoints, multicenter kit reproducibility across independent labs, and a clear pivotal design with Quest ready as central lab. Pair that with Germany metrics from DoctorBox 1,000,000 plus users and 10M plus results, and investors can model 2026 instead of guessing.

Which single step would move you first: firm feasibility date, published kit concordance, or a Quest readiness update?

Not financial advice. Do your own research.